Cargando…

Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease

BACKGROUND: To learn from the crisis caused by the coronavirus disease (COVID-19) pandemic and be prepared for future pandemics, it is important to investigate the impact of this period on the wellbeing of patients with inflammatory bowel disease (IBD). AIMS: To describe the health-related quality o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paulides, Emma, Pasma, Annelieke, Erler, Nicole S., van Eijk, Rachel L. A., de Vries, Annemarie C., van der Woude, C. Janneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237768/ https://www.ncbi.nlm.nih.gov/pubmed/34181168 http://dx.doi.org/10.1007/s10620-021-07118-8

Ejemplares similares

Inflammatory bowel disease negatively impacts household and family life
por: Paulides, Emma, et al.
Publicado: (2021)

Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events
por: Lie, Mitchell R. K. L., et al.
Publicado: (2020)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
por: Pauwels, Renske W. M., et al.
Publicado: (2020)

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease
por: Vogelaar, Lauran, et al.
Publicado: (2009)

Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
por: Sleutjes, Jasmijn A. M., et al.
Publicado: (2021)

Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation
por: Sleutjes, Jasmijn A M, et al.
Publicado: (2022)

Modulatory Effects of Pregnancy on Inflammatory Bowel Disease
por: van der Giessen, Janine, et al.
Publicado: (2019)

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study
por: Paulides, Emma, et al.
Publicado: (2022)

The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review
por: Paulides, Emma, et al.
Publicado: (2020)

SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: van de Pol, Natasja, et al.
Publicado: (2023)

Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry
por: Looijen, Agnes E M, et al.
Publicado: (2023)

A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models
por: van der Giessen, Janine, et al.
Publicado: (2019)

Systematic review with meta‐analysis: effect of inflammatory bowel disease therapy on lipid levels
por: Sleutjes, Jasmijn A. M., et al.
Publicado: (2021)

Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2023)

Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study
por: van den Brink, Gertrude, et al.
Publicado: (2019)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
por: Lie, Mitchell R. K. L., et al.
Publicado: (2018)

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life
por: Kanis, Shannon Linda, et al.
Publicado: (2021)

Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2021)

Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters
por: Vogelaar, Lauran, et al.
Publicado: (2017)

Intestinal resection rates in Crohn’s disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFα
por: Beelen, Evelien M J, et al.
Publicado: (2020)

Impact of the First SARS-CoV-2 Lockdown on Adherence to Biological Treatment in Patients with Immune-Mediated Inflammatory Diseases in the Netherlands
por: van der Groef, Romy, et al.
Publicado: (2023)

Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease
por: Pauwels, Renske W M, et al.
Publicado: (2021)

Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey
por: Baars, J. E., et al.
Publicado: (2012)

Pregnane X receptor activation constrains mucosal NF-κB activity in active inflammatory bowel disease
por: Deuring, J. Jasper, et al.
Publicado: (2019)

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease
por: Beelen, Evelien M J, et al.
Publicado: (2023)

Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic
por: De Lima-Karagiannis, A, et al.
Publicado: (2020)

Self‐efficacy did not predict the outcome of the transition to adult care in adolescents with inflammatory bowel disease
por: van den Brink, Gertrude, et al.
Publicado: (2018)

Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case–control study
por: Gerrits, Monique M., et al.
Publicado: (2011)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
por: Doornekamp, Laura, et al.
Publicado: (2020)

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
por: van der Valk, Mirthe E., et al.
Publicado: (2016)

Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2022)

Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
por: Nuij, V. J. A. A., et al.
Publicado: (2017)

Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice
por: Pauwels, Renske Wilhelmina Maria, et al.
Publicado: (2020)

High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
por: Dahlerup, Jens Frederik, et al.
Publicado: (2016)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Anemia and Iron Deficiency in Outpatients with Inflammatory Bowel Disease: Ubiquitous Yet Suboptimally Managed
por: Loveikyte, Roberta, et al.
Publicado: (2022)

Cholecystectomy Risk in Crohn’s Disease Patients After Ileal Resection: a Long-term Nationwide Cohort Study
por: Goet, Jorn C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ck77mjnuqti1ddueljie15rghj